Biogen Inc. (NASDAQ: BIIB) reported its second quarter 2024 earnings results today. Total revenue of $2.5 billion was flat at actual currency and up 1% at constant currency compared to the same period a year ago. Net income attributable to Biogen Inc. was $583.6 million compared to $591.6 million last year. GAAP EPS dropped 2% […]
“Biogen Inc. (NASDAQ: BIIB) reported its second quarter 2024 earnings results today. Total revenue of $2.5 billion was flat at actual currency and up 1% at constant currency compared to the same period a year ago. Net income attributable to Biogen Inc. was $583.6 million compared to $591.6 million last year. GAAP EPS dropped 2% […]
· August 1, 2024
Biogen Inc. (NASDAQ: BIIB) reported its second quarter 2024 earnings results today.
Total revenue of $2.5 billion was flat at actual currency and up 1% at constant currency compared to the same period a year ago.
Net income attributable to Biogen Inc. was $583.6 million compared to $591.6 million last year.
GAAP EPS dropped 2% to $4.00 while adjusted EPS rose 31% to $5.28 compared to last year.
For the full year of 2024, the company expects total revenue to decline by a low-single digit percentage. Adjusted EPS is expected to be $15.75-16.25.
